Favipiravir inhibits Mayaro virus infection in mice /Bengue, Michèle Pintong, A. /Liégeois, Florian Nougairede, A. /Hamel, Rodolphe /Pompon, Julien Lamballerie, X. de Roques, P. Choumet, V. /Missé, Dorothée alphavirus arbovirus mayaro favipiravir antiviral drug Mayaro virus (MAYV) is an emergent alphavirus that causes MAYV fever. It is often associated with debilitating symptoms, particularly arthralgia and myalgia. MAYV infection is becoming a considerable health issue that, unfortunately, lacks a specific antiviral treatment. Favipiravir, a broad-spectrum antiviral drug, has recently been shown to exert anti-MAYV activity in vitro. In the present study, the potential of Favipiravir to inhibit MAYV replication in an in vivo model was evaluated. Immunocompetent mice were orally administrated 300 mg/kg/dose of Favipiravir at pre-, concurrent-, or post-MAYV infection. The results showed a significant reduction in infectious viral particles and viral RNA transcripts in the tissues and blood of the pre- and concurrently treated infected mice. A significant reduction in the presence of both viral RNA transcript and infectious viral particles in the tissue and blood of pre- and concurrently treated infected mice was observed. By contrast, Favipiravir treatment post-MAYV infection did not result in a reduction in viral replication. Interestingly, Favipiravir strongly decreased the blood levels of the liver disease markers aspartate- and alanine aminotransferase in the pre- and concurrently treated MAYV-infected mice. Taken together, these results suggest that Favipiravir is a potent antiviral drug when administered in a timely manner. 2021 text https://www.documentation.ird.fr/hor/fdi:010083796 fdi:010083796 Bengue Michèle, Pintong A., Liégeois Florian, Nougairede A., Hamel Rodolphe, Pompon Julien, Lamballerie X. de, Roques P., Choumet V., Missé Dorothée. Favipiravir inhibits Mayaro virus infection in mice. 2021, 13 (11), 2213 [17 ] EN